Poster List
P001
Engineered cells for cancer immunotherapy
Semliki Forest virus-based vaccines encoding CAR antigens to foster the activation, expansion and antitumor efficacy of CAR-T cells.
A Covo, Program of Immunology and Immunotherapy, CIMA / Instituto de Investigación Sanitaria de Navarra (IdiSNA)
P002
Engineered cells for cancer immunotherapy
Base edited allogenic CAR-T cells for the treatment of CD19+ malignancies
B Díez, CIEMAT/CIBERER/IIS-FJD
P003
Engineered cells for cancer immunotherapy
Drug screening approach to identify new hits to revert the resistant phenotype in cancer cells of CAR-T cell destruction.
J Marañon, CIMA / IdiSNA
P004
Engineered cells for cancer immunotherapy
Exploiting transient mRNA expression of proinflammatory cytokines in adoptive T cell therapy for peritoneal carcinomatosis
L Arrizabalaga, Centro de Investigacion Medica Aplicada (CIMA)
P005
Engineered cells for cancer immunotherapy
Competition of co-transduced CARs for cellular resources in dual-targeting CAR T cells
N Barceló-Genestar, IDIBAPS
P006
Engineered cells for cancer immunotherapy
Identification of molecular mechanisms governing CAR-T cell response in MM patients using single cell transcriptomics
L Jordana-Urriza, Hemato-Oncology Program. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain
P007
Engineered cells for cancer immunotherapy
Identification of CD3 oligonucleotide-based aptamers that enhance T-cell expansion and prolong the survival of low-affinity TCR-reactive lymphocytes for use in adoptive T-cell therapy
M Hernández, CIMA
P009
Engineered cells for cancer immunotherapy
Improving exosome production and immunogenicity for more effective CAR T cell therapy
P Heredia, Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), Granada, Spain / Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain
P010
Engineered cells for cancer immunotherapy
Improved packaging cells by disruption of pro-apoptotic genes
J Ruiz-de-Francisco, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO),PTS, Avda. de la Ilustración 144, 18016 Granada, Spain
P011
Engineered cells for cancer immunotherapy
CAR T therapy efficacy in hypoxic osteosarcoma spheroids.
P Garcia-Rodriguez, Instituto de Salud Carlos III
P012
Engineered cells for cancer immunotherapy
Memory features of CAR19-enginereed natural killer cells as new immunomodulators of the safety and efficacy of CAR-NK based therapies
D Barriales, Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, 48960, Spain / Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, 48903, Spain
P013
Engineered cells for cancer immunotherapy
Bioinformatic target identification and CAR-NK immunotherapy design and development for Head and Neck Squamous Cell Cancer (HNSCC)
M Hernández-Gamarra, Genomic Medicine, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain. / C005, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, 15706, Spain.
P014
Engineered cells for cancer immunotherapy
CRISPR-mediated targeting of IL15 to the PD1 locus to improve the phenotype of CD19 CAR T cells.
M Cortijo-Gutiérrez, Gene and Cell Therapy Group. Genomic medicine department, GENYO, Granada, 14016, Spain.
P015
Engineered cells for cancer immunotherapy
Phosphatidylserine as a tumor target for CAR-T cell therapy in solid tumors.
C Martín-Otal, Centro de Investigacion Medica Aplicada (CIMA)
P016
Engineered cells for cancer immunotherapy
Generation of CD19 CAR variants with NK cell specific motifs to determine the best choice for treating relapsed or refractory leukemias and lymphomas
L Herrera, Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain. / Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. / Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
P017
Engineered cells for cancer immunotherapy
Generating NK cells in vitro from cord blood units in a feeder free GMP system
A Saez de Camara, Grupo de Terapia Celular, Células Madre y Tejidos, Centro Vasco de Transfusión y Tejidos Humanos, IIS Biocruces Bizkaia, Galdakao, Spain. / Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
P018
Engineered cells for cancer immunotherapy
A comparative study of non-viral systems to improve gene delivery in human NK cells
M Burón, Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain / Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain / Cell Biology and Histology Department, University of the Basque Country (UPV/EHU), Leioa, Spain / Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de investigación Lascaray ikergunea, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain / Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, Vitoria-Gasteiz, Spain / Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
P019
Engineered cells for cancer immunotherapy
Generating NKG2D-CAR-transduced natural killer (NK) cells for treating osteosarcoma
A Etxebarria, Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain. / Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. / Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
P020
Engineered cells for cancer immunotherapy
BCMA CAR-T cell phenotype and functionality is affected by disease stage of multiple myeloma patients
P Rodriguez-Marquez, Hemato-Oncology Program. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain.
P021
Engineered cells for cancer immunotherapy
Tethered IL-15-IL15R augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in immunocompetent mice
I Sánchez-Moreno, Centro de Investigacion Medica Aplicada (CIMA)
P022
Gene & cell therapy for haematological disorders
Disease-corrected hematopoietic progenitors from APDS2 syndrome derived iPS cells
I Romayor, BioCruces/Hospital Universitario Cruces / Basque Center for Blood Transfusion and Human Tissues (CVTTH) / University of the Basque Country School of Medicine / Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII)
P023
Gene & cell therapy for haematological disorders
Lentiviral-mediated gene therapy for Diamond-Blackfan anemia: one step closer to the clinic
S Navarro, CIEMAT/CIBERER / IIS-FJD, UAM
P024
Gene & cell therapy for haematological disorders
Lentiviral-mediated gene therapy restores telomere homeostasis in ex vivo assays on dyskeratosis congenita-like CD34+ cells
G Guenechea, Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid 28040. Spain.
P025
Gene & cell therapy for haematological disorders
Memory Universal CD19-CAR T cells: a new strategy against B-cell malignancies
K Pavlovic, Pfizer Centre for Genomics and Oncological Research (GENYO) / Maimonides Biomedical Research Institute of Cordoba (IMIBIC)
P026
Gene & cell therapy for neurological disorders
Strategies to obtain preferential transgene expression in GABAergic neurons using adenoviral vectors
R Hernandez-Alcoceba, Universidad de Navarra-CIMA
P027
Gene & cell therapy for neurological disorders
In vivo testing of a novel anti-aging aKlotho derivative for the treatment of Alzheimer’s disease in a mouse model
J Esandi, Institut de Neurociències (INc), Universitat Autònoma Barcelona, Bellaterra, 08193, Spain
P028
Gene & cell therapy for neurological disorders
AAV9-Mediated expression of secreted Klotho reduced several aging-associated phenotypes and increased longevity
J Roig-Soriano, Institut de Neurociènces (INc), Universitat Autònoma Barcelona, Bellaterra, Spain
P029
Gene & cell therapy for neurological disorders
AAV-based gene therapy strategy for hereditary spastic paraplegia type 52 (SPG52)
L Rodriguez-Estevez, Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona / Institut de Neurociències (INc), Universitat Autònoma de Barcelona / Vall d'Hebron Research Institute (VHIR), Research Group on Gene Therapy at Nervous System
P030
Gene & cell therapy for neurological disorders
A new gene therapy approach for the treatment of Sandhoff and Tay-Sachs diseases
G Elias, Center for Animal Biotechnology and Gene Therapy / Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona
P031
Gene & cell therapy for neurological disorders
ASD phenotype reversal through the optimisation of multiple delivery methods in 2D and 3D cellular models: genome editing-based method as a therapeutic approach.
L F Pedrera-Garbayo, Genomic Medicine, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain / C005, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, 15706, Spain
P032
Gene & cell therapy for neurological disorders
Therapeutic effect of sKL gene therapy strategy to treat aging and neurodegeneration
B Almolda, Institut de Neurociències (INc), Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain / Vall d'Hebron Institut de Recerca (VHIR), Research Group on Gene Therapy at Nervous System, Barcelona, 08035, Spain / Unitat Histologia Mèdica, Universitat Autònoma de Barcelona, Bellaterra, Spain
P033
Gene & cell therapy for neurological disorders
Characterization of striatal progenitors for the search of a cell-therapy based strategy for Huntington´s disease.
O Varea, Universitat de Barcelona -IDIBAPS
P034
Gene & cell therapy for neurological disorders
4-Deep Brain Reconstruction: a novel therapy for neurodegenerative diseases
A Louail, Laboratory of Stem Cells and Regenerative Medicine, Department of Biomedical Sciences; Creatio - Production and Validation Center of Advanced Therapies, Faculty of Medicine and Health Sciences; and Institute of Neurosciences, University of Barcelona; and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, 08036, Spain.
P035
Gene & cell therapy for neurological disorders
Tandem promoters design, a novel gene therapy for the treatment of multisystem diseases.
D Herrero, Centro de Investigacion Medica Aplicada (CIMA)
P036
Gene & cell therapy for neurological disorders
Development of advanced therapies and 2D and 3D in vitro models generated from ultra-rare variants and VUS in rare neurodevelopmental disorders
A Salgado-Roo, Genomic Medicine, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain / C005, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, 15706, Spain
P038
Gene & cell therapy of metabolic diseases
Substrate reduction gene therapy rescues glutaric aciduria type I in mice.
E Segur-Bailach, IDIBAPS / CIBERER
P039
Gene & cell therapy of metabolic diseases
HSPCs targeted insertion in CX3CR1 enhances myeloid expression of integrated cassettes
I Ramos-Hernández, GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia / Fundacion Publica Andaluza Progreso y Salud
P040
Gene & cell therapy of metabolic diseases
Engineering new gene therapy tools for Pompe Disease
F J Molina-Estevez, Genomic Medicine Department. GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnólogico Ciencias de la Salud, Av. de la Ilustración 114, 18016 Granada; Spain. / Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain / Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO)
P041
Gene & cell therapy of metabolic diseases
Interleukin 10 gene hydrofection in human colonic segments affected with Crohn’s disease
L Sendra, Pharmacogenetics and Gene Therapy Unit, Instituto de Investigación Sanitaria La Fe / Gene Therapy and Pharmacogenomics, Department of Pharmacology, Universitat de València
P042
Gene & cell therapy of metabolic diseases
Therapeutic efficacy of the combination of VTX-801 and D-Penicillamine for Wilson’s disease
O Murillo, CIMA
P043
Gene & cell therapy of metabolic diseases
Therapeutic efficacy of VTX-801 in mice with advanced-stage Wilson's disease
O Murillo, CIMA
P044
Gene & cell therapy of metabolic diseases
Improvement of progressive familiar intrahepatic cholestasis type 2 (PFIC2) via AAV-mediated hepatic BSEP expression in mice
A Molina, CIMA / Institute for Sanitary Research (IdiSNA)
P045
Gene & cell therapy of metabolic diseases
Characterization of the role of the transcriptional regulator Senataxin on AAV-mediated transgene expression
S Isola, Centro de Investigacion Medica Aplicada (CIMA)
P046
Gene editing
RNA therapy with SM3, a small hairpin of lncRNA NIHCOLE, can promote ligation of DNA double-strand breaks.
L Prats-Mari, CIMA
P047
Gene editing
AAV-SaCas9 Nickase targeting Hao1 is a safe and efficient therapy for Primary hyperoxaluria type 1 with a low AAV integration rate
L Torella, Gene Therapy and Regulation of Gene Expression Program, Center for Applied Medical Research (CIMA) - University of Navarra (UNAV); Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona 31008, Spain.
P048
Gene editing
Evaluation of CRISPR/CasRx-mediated Hao1 RNA editing for Primary hyperoxaluria type 1 therapy in vivo
L Torella, Gene Therapy and Regulation of Gene Expression Program, Center for Applied Medical Research (CIMA) - University of Navarra (UNAV); Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona 31008, Spain.
P049
Gene editing
Optimizing analysis pipelines for the detection of adeno-associated virus (AAV) integration into CRISPR-induced DNA breaks
M Bilbao-Arribas, Centro de Investigacion Medica Aplicada (CIMA) / Instituto de Investigación Sanitaria de Navarra (IdiSNA)
P050
Gene editing
Developing new mouse gene editing tools to assess Pyruvate Kinase Deficiency stem cell gene editing in a mouse model of the disease
J C Segovia-Sanz, Cell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain / Unidad Mixta de Terapias Avanzadas. Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
P051
Gene editing
ldrB gene: elucidating mechanism of action of a suicide gene.
Y Jiménez Martínez, Universidad de Granada
P052
Gene editing
Combinatorial effect of Polypurine Reverse Hoogsteen against MYC and KRAS oncogenes in the human PC-3 cancer cell line
S Valiuska, University of Barcelona
P053
Gene editing
Splicing factors SF3B1 and SRSF-1 play a role in estrogen receptor α splicing and gene regulation in breast cancer cells
J Cullell, University of Barcelona
P054
Gene editing
Generation of brain organoids and zebrafish models to determine and reverse ASD-related phenotypes
S Veiga-Rúa, Genomic Medicine, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, 15706, Spain / ZebraBioRes, Zoology, Genetics and Anthropology Department, University of Santiago de Compostela, Lugo, 27002, Spain / C005, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, 15706, Spain
P055
Gene editing
Generation of testicular organoids from Klinefelter Syndrome patient testis
I Romayor, Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain / Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain / Cell Biology and Histology Department, University of the Basque Country (UPV/EHU), Leioa, Spain / Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
P056
Gene editing
Prime editing as a potential treatment for autosomal dominant polycystic kidney disease in mice
F Gómez-García, Instituto de Investigación Sanitaria de Santiago / Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas
P057
Gene editing
CRISPR/Cas13-RNP knockdown of oncogenic proteins: A promising approach for cancer therapy
M López-Valls, Nanobiotechnology, Fundación IMDEA Nanociencia, Madrid, 28049, Spain
P058
Gene editing
Non-viral CRISPR delivery using magnetic nanoparticles
C Escalona-Noguero, Imdea Nanociencia, Madrid Madrid, Spain
P059
in vivo gene & cell therapy non viral
Analysis of lncRNA translation to develop RNA anticancer vaccines
P Theunissen, CIMA
P060
in vivo gene & cell therapy non viral
mRNA-based therapy in a new model of variegate porphyria in rabbits
D Jericó, Centro de Investigacion Medica Aplicada (CIMA)
P061
in vivo gene & cell therapy non viral
Suicide gene therapy targeting cancer stem cells to eradicate cancer
H Boulaiz, Instituto de Investigación Biosanitaria ibs .GRANADA / Universidad de Granada / Research Unit “Modeling Nature” (MNat), University of Granada
P062
in vivo gene & cell therapy non viral
Magnetic targeting of iron oxide nanoparticles to the kidneys
A Bazo, Group of gene therapy of renal diseases and study of the N-terminal acetylation of proteins, Centro de Investigación Médica Aplicada (CIMA) - Universidad de Navarra, Pamplona, 31008, Spain
P063
in vivo gene & cell therapy non viral
Towards post-ischemic cardiac regeneration with microRNA therapy and customized DNA-based nanostructures
M Sánchez, Institute of Nanoscience of Aragon (University of Zaragoza) / Engineering Research Institute of Aragon / Health Research Institute of Aragon
P064
in vivo gene & cell therapy non viral
Non-viral delivery of microRNA therapies for cardiac dysfunction using DNA nanostructures
N Hernández-Bellido, Engineering Research Institute of Aragon (I3A) (University of Zaragoza) / Institute for Health Research Aragón (IIS Aragón)
P065
in vivo gene & cell therapy non viral
Hepatic hydrofection of naked hIL10 gene in pig to study its immunomodulatory effect in liver transplantation scenario
L Sendra, Pharmacogenetics and Gene Therapy Unit, Instituto de Investigación Sanitaria La Fe / Gene Therapy and Pharmacogenomics, Department of Pharmacology, Universitat de València
P066
in vivo gene & cell therapy non viral
Isolation and characterization of milk exosomes for their use in gene therapy
A Redrado-Osta, IIS Aragón
P067
in vivo gene & cell therapy non viral
Comparison of methodologies for exosome extraction: Ultracentrifugation versus Size Exclusion Chromatography (SEC)
B Azanza-Hernandez, Universidad de Zaragoza
P068
Manufacturing
Mimicking the tumor microenvironment with extracellular matrices: new 3D models for cancer advanced therapies research
L de Lara-Peña, Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada. / Biopathology and Regenerative Medicine Institute (IBIMER) / Biosanitary Investigation Institute (Ibs.GRANADA) / Excellence Research Unit “Modelling Nature” (Mnat)
P069
Manufacturing
Establishment of airway epithelium organoids for lung disease modelling
P Alonso-Alvarez, Biodonostia Institute
P070
Manufacturing
Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use
S Torrents, Banc de Sang i Teixits / Vall d'Hebron Research Institute (VHIR)
P071
Manufacturing
Metastasis-on-a-chip for the study of the metastatic process: one step closer to precision medicine
J Ruiz-Espigares, Universidad de Granada
P072
Manufacturing
Addressing the Challenges of Capillary Electrophoresis for AAV Purity Characterization
A Carreras, Viralgen Vector Core
P073
Manufacturing
Optimizing analytical methods for product characterization during rAAV manufacturing process
A Manterola, Viralgen Vector Core
P074
Manufacturing
Identification of specific AAV9 capsid residues for chemical modification to enhance the properties of the recombinant vector
S Milagros, CIMA / Universidad de Navarra
P075
Manufacturing
TAAV-manufactured enzymatic DNA: an efficient technology to overcome rAAV manufacturing challenges
K Orange, TAAV Manufacturing Solutions
P076
Manufacturing
Improved methods and optimized design for CRISPR Cas9 and Cas12a homology-directed repair Integrated DNA Technologies, Coralville, IA, 52241 USA * Corresponding author: mschubert@idtdna.com
M Schubert, University of Iowa
P077
Manufacturing
Advanced characterization of TAAV-manufactured enzymatic DNA final product by HPLC
M Eceiza, TAAV Manufacturing Solutions
P078
Manufacturing
The impact of the new Annex I for the manufacture of sterile medicinal products on the production of advanced therapy medicinal products.
J Alonso, Universidad del País Vasco (UPV/EHU)
P079
Oncolytic viruses & cancer immunotherapy
Phase I trial of DNX-2440 oncolytic adenovirus in patients with first or second recurrence of glioblastoma: preliminary results.
J Gállego Pérez-Larraya, Clinica Universidad de Navarra
P080
Oncolytic viruses & cancer immunotherapy
Optimized protocol of menstrual blood-derived mesenchymal stem cell isolation and amplification to combine with oncolytic adenovirus for cancer treatment
L Moya-Borrego, IDIBELL-ICO
P081
Oncolytic viruses & cancer immunotherapy
Oncolytic adenovirus coding for MICA enhances immune responses against tumors
P Fiol, IDIBELL-ICO
P082
Oncolytic viruses & cancer immunotherapy
Intra-tumoral delivery of mRNA encoding IL-12-fused to diabodies targeting CSF1R and PD-L1 exert potent anti-tumor efficacy while restraining systemic exposure to IL-12.
C A DI TRANI, Centro de Investigacion Medica Aplicada (CIMA) / Navarra Institute for Health Research (IDISNA)
P083
Oncolytic viruses & cancer immunotherapy
Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease
A del Canizo, Universitat de Barcelona / Fundacion Idibell
P084
Oncolytic viruses & cancer immunotherapy
Understanding the immune microenvironment of pediatric brain tumors after virotherapy
R Hernandez-Osuna, Universidad de Navarra / CIMA / University Clinic of Navarra
P085
Oncolytic viruses & cancer immunotherapy
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 as a new therapeutic regime for pediatric high-grade gliomas
D de la Nava, Universidad de Navarra / Centro de Investigacion Medica Aplicada (CIMA) / Instituto de Investigación Sanitaria de Navarra (IdiSNA) / Clinica Universidad de Navarra
P086
Oncolytic viruses & cancer immunotherapy
Oncolytic virus and CAR-T cells combination therapy to treat solid tumors.
P Garcia-Rodriguez, Instituto de Salud Carlos III
P087
Oncolytic viruses & cancer immunotherapy
Oncolytic adenovirus Delta-24-RGD engineered to express OX40L promotes antitumor immune response in DMG models
I Ausejo-Mauleon, Clinica Universidad de Navarra / Centro de Investigacion Medica Aplicada (CIMA)
P088
Oncolytic viruses & cancer immunotherapy
Enhanced antitumor efficacy of CAR T cell therapy by combination with a new oncolytic adenovirus, ISC301
A Morales-Molina, Instituto de Salud Carlos III
P089
Oncolytic viruses & cancer immunotherapy
Targeting the Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Intrinsic Pontine Gliomas
S Labiano, Department of Pediatrics, Clinica Universidad de Navarra, 31008 Pamplona, Spain / Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
P090
Oncolytic viruses & cancer immunotherapy
Reprogramming the immunosuppressive footprint of tumor-associated myeloid cells enhances gene immunotherapy of cancer based on PD-L1/PD-1 blockade
E Blanco, Oncoimmunology Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA). / Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Cancer Center Clínica Universidad Navarra (CCUN), and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona,Spain.
P091
Oncolytic viruses & cancer immunotherapy
Evaluation of toxicity and biodistribution of oncolytic adenovirus VCN-01 after intracranial injection in Syrian hamsters
D Palacios-Alonso, Universidad de Navarra
P092
Oncolytic viruses & cancer immunotherapy
Exogenous miRNAs targeting proliferation pathways as therapeutic agents against malignant melanoma
J Peña-Martín, Universidad de Granada
P093
Oncolytic viruses & cancer immunotherapy
Oncolytic adenovirus armed with PDT activate nucleoside prodrugs to induce effective anticancer effects
M Parés, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)
P094
Regenerative medicine
Composite human cardiac minitissues are a representative 3D model of anthracycline cardiotoxicity
P Montero-Calle, Centro de Investigacion Medica Aplicada (CIMA) / IdiSNA (Instituto de Investigación Sanitaria de Navarra)
P095
Regenerative medicine
Generation of heart and vascular system from pluripotent stem cells by blastocyst complementation.
P Barlabé, Program of Regenerative Medicine, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, 31008, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, 31008, Spain.
P096
Regenerative medicine
Development and characterization of novel antioxidant biomaterials for cardiac tissue engineering
M P Araluce, Center for Applied Medical Research / Universidad de Navarra
P097
Regenerative medicine
Capturing the peri-implantation stages of human embryo development in naive pluripotent stem cell cultures
M Moya-Jódar, Program of Regenerative Medicine, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona 31008, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona 31008, Spain
P098
Regenerative medicine
Bioinks based on decellularised extracellular matrix from cells for osteochondral grafts
J A Marchal, Universidad de Granada / Instituto de Investigación Biosanitaria ibs.GRANADA / BioFab i3D—Biofabrication and 3D (Bio)Printing Laboratory / Excellence Research Unit “Modeling Nature” (MNat)
P099
Regenerative medicine
Mesenchymal stem cells as cell therapy for canine degenerative joint disease
B D Tomeo-Martín, Universidad Alfonso X El Sabio
P100
Regenerative medicine
Towards a high-throughput and easy-to-use system for human cardiotoxicity tracking through the use of microfabrication and hiPSCs-derived cardiovascular phenotypes
P Montero, Center for Applied Medical Research
P101
Regenerative medicine
Generation of a characterizated collection of organoids in the Biobank of the Aragon Health System
M M Encabo-Berzosa, Instituto Aragonés de Ciencias de la Salud / Biobanco del Sistema de Salud de Aragón
P102
Regenerative medicine
In silico sex deconvolution in single-cell RNA-seq data
J Abante, Universitat de Barcelona / Stanford University
P103
Regenerative medicine
Accelerating the research and development of Advanced Therapy Medicinal Products (ATMPs): approaches to regulatory harmonization emerging from the ARDAT consortium.
C J Mann, Asphalion SL
P104
Regenerative medicine
Evaluation the impact of matrix surfaces on iPSCs differentiation into hepatocyte like cells
E Villanueva-Badenas, Instituto de Investigacion sanitaria La Fe
P105
Regenerative medicine
Vascular stromal fraction-derived MSCs as a source of lymphatic endothelial progenitor cells (LEPCs)
I Arriola-Alvarez, Biodonostia Institute
P107
Regenerative medicine
Comparison of different methods for isolation and purification of monocytes from peripheral blood
A Arqué, Laboratory of Stem Cells and Regenerative Medicine, Department of Biomedical Sciences; Creatio - Production and Validation Center of Advanced Therapies, Faculty of Medicine and Health Sciences; and Institute of Neurosciences, University of Barcelona; and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, 08036, Spain. / ECNOLOGIA REGENERATIVA QREM SL, Barcelona, 08014, Spain.
P108
Regenerative medicine
Regulatory requirements for genetically modified organism (GMO) applications: tips and tricks for global ATMP development
L Mendieta, Asphalion SL
P109
in vivo gene & cell therapy non viral
Vitamin E and sphingomyelin-based nanoemulsions for in vivo mRNA delivery
L Taina-González, DIVERSA Technologies / Universidad de Santiago de Compostela